Abrocitinib

Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC50s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC50, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease[1].

Product Specifications

CAS Number

[1622902-68-4]

Product Name Alternative

PF-04965842

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

JAK

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Abrocitinib.html

Purity

99.26

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CN([C@H]1C[C@@H](NS(CCC)(=O)=O)C1)C2=C3C(NC=C3)=NC=N2

Molecular Formula

C14H21N5O2S

Molecular Weight

323.41

Precautions

H302, H315, H319, H335

References & Citations

[1]Vazquez ML, et al. Identification of N-{cis-3-[Methyl (7H-pyrrolo[2,3-d]pyrimidin-4-yl) amino]cyclobutyl}propane-1-sulfonamide (PF-04965842) : A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. J Med Chem. 2018 Feb 8;61 (3) :1130-1152.